The collaboration will allow Bristol Myers Squibb to capitalize on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.

Codexis, Inc., a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announce a partnership to engineer enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA.

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against COVID-19.

GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials.

Waters Corporation has introduced the Waters™ Arc™ HPLC System, a new high-performance liquid chromatograph (HPLC) for routine testing in the pharmaceutical, food, academic and materials markets.

Infectivity assays have shown that Affimer reagents can prevent infection of human cells by a SARS-CoV-2 model virus.

Corning’s pre-coated Matrigel matrix-3D plates aim to streamline workflows and deliver a more consistent and convenient solution for high throughput environments.

The companies have teamed up to promote the use of protein footprinting technologies, products, and contract research services in biopharmaceutical research and development.

Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has announced it has signed a supply agreement with AstraZeneca UK Ltd. (“AstraZeneca”) to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222,

AMSBIO has reported on the pioneering work by researchers at the University of Sheffield, UK to measure the interaction between the SARS-CoV-2 Spike S1 protein receptor binding domain and heparin.